-
1
-
-
84958822343
-
-
National Institute for Health and Care Excellence: Rheumatoid arthritis: the management of rheumatoid arthritis in adults. NICE guidelines [CG79] NICE Website, [cited 2015 11th February]. Available from
-
National Institute for Health and Care Excellence: Rheumatoid arthritis: the management of rheumatoid arthritis in adults. NICE guidelines [CG79] NICE Website 2009 [cited 2015 11th February]. Available from: http://www.nice.org.uk/TA130.
-
(2009)
-
-
-
3
-
-
84958770453
-
Anakinra Product Approval Information -Licensing Action 2001
-
cited, 19th December, Available from
-
US Food and Drug Administration (FDA):Anakinra Product Approval Information -Licensing Action 2001 [cited 2013 19th December]. Available from: http://www.fda. gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm080650.htm.
-
(2013)
-
-
-
4
-
-
67149130597
-
Anakinra for rheumatoid arthritis: a systematic review
-
MERTENS M, SINGH JA: Anakinra for rheumatoid arthritis: a systematic review. J Rheumatol 2009; 36: 1118-25.
-
(2009)
J Rheumatol
, vol.36
, pp. 1118-1125
-
-
Mertens, M.1
Singh, J.A.2
-
5
-
-
84868454136
-
Timing the therapeutic window of opportunity in early rheumatoid arthritis: proposal for definitions of disease duration in clinical trials
-
RAZA K, SABER TP, KVIEN TK, TAK PP, GERLAG DM: Timing the therapeutic window of opportunity in early rheumatoid arthritis: proposal for definitions of disease duration in clinical trials. Ann Rheum Dis 2012; 71: 1921-3.
-
(2012)
Ann Rheum Dis
, vol.71
, pp. 1921-1923
-
-
Raza, K.1
Saber, T.P.2
Kvien, T.K.3
Tak, P.P.4
Gerlag, D.M.5
-
6
-
-
0037103342
-
Long-term outcome in rheumatoid arthritis: a simple algorithm of baseline parameters can predict radiographic damage, disability, and disease course at 12-year followup
-
DROSSAERS-BAKKER KW, ZWINDERMAN AH, VLIET VLIELAND TP et al.: Long-term outcome in rheumatoid arthritis: a simple algorithm of baseline parameters can predict radiographic damage, disability, and disease course at 12-year followup. Arthritis Rheum 2002; 47: 383-90.
-
(2002)
Arthritis Rheum
, vol.47
, pp. 383-390
-
-
Drossaers-Bakker, K.W.1
Zwinderman, A.H.2
Vliet Vlieland, T.P.3
-
7
-
-
84903536740
-
Radiological outcomes in randomized controlled trials on biologic therapies for rheumatoid arthritis: a narrative review.
-
BIZZI E, MASSAFRA U, LAGANA B et al.:Radiological outcomes in randomized controlled trials on biologic therapies for rheumatoid arthritis: a narrative review. Clin Rheumatol 2014; 33: 877-84.
-
(2014)
Clin Rheumatol
, vol.33
, pp. 877-884
-
-
Bizzi, E.1
Massafra, U.2
Lagana, B.3
-
8
-
-
0023694150
-
Correlation of plasma interleukin 1 levels with disease activity in rheumatoid arthritis
-
EASTGATE JA, SYMONS JA, WOOD NC, GRINLINTON FM, di GIOVINE FS, DUFF GW: Correlation of plasma interleukin 1 levels with disease activity in rheumatoid arthritis. Lancet 1988; 2: 706-9.
-
(1988)
Lancet
, vol.2
, pp. 706-709
-
-
Eastgate, J.A.1
Symons, J.A.2
Wood, N.C.3
Grinlinton, F.M.4
Di Giovine, F.S.5
Duff, G.W.6
-
9
-
-
0026684213
-
Determination of cytokines in synovial fluids: correlation with diagnosis and histomorphological characteristics of synovial tissue
-
KAHLE P, SAAL JG, SCHAUDT K, ZACHER J, FRITZ P, PAWELEC G: Determination of cytokines in synovial fluids: correlation with diagnosis and histomorphological characteristics of synovial tissue. Ann Rheum Dis 1992; 51: 731-4.
-
(1992)
Ann Rheum Dis
, vol.51
, pp. 731-734
-
-
Kahle, P.1
Saal, J.G.2
Schaudt, K.3
Zacher, J.4
Fritz, P.5
Pawelec, G.6
-
10
-
-
0032752705
-
IL-1 alpha beta blockade prevents cartilage and bone destruction in murine type II collagen- induced arthritis, whereas TNF-alpha blockade only ameliorates joint inflammation
-
JOOSTEN LA, HELSEN MM, SAXNE T, van De LOO FA, HEINEGARD D, van Den BERG WB: IL-1 alpha beta blockade prevents cartilage and bone destruction in murine type II collagen- induced arthritis, whereas TNF-alpha blockade only ameliorates joint inflammation. J Immunol 1999; 163: 5049-55.
-
(1999)
J Immunol
, vol.163
, pp. 5049-5055
-
-
Joosten, L.A.1
Helsen, M.M.2
Saxne, T.3
Van De Loo, F.A.4
Heinegard, D.5
Van Den Berg, W.B.6
-
11
-
-
0034083128
-
A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores
-
JIANG Y, GENANT HK, WATT I et al.: A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum 2000; 43:1001-9.
-
(2000)
Arthritis Rheum
, vol.43
, pp. 1001-1009
-
-
Jiang, Y.1
Genant, H.K.2
Watt, I.3
-
12
-
-
84931571929
-
Anakinra treatment in drug-resistant Behcet's disease: a case series.
-
CANTARINI L, VITALE A, SCALINI P et al.:Anakinra treatment in drug-resistant Behcet's disease: a case series. Clin Rheumatol 2015; 34: 1293-301.
-
(2015)
Clin Rheumatol
, vol.34
, pp. 1293-1301
-
-
Cantarini, L.1
Vitale, A.2
Scalini, P.3
-
13
-
-
84875963811
-
Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review.
-
Ter HAAR N, LACHMANN H, OZEN S et al.:Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review. Ann Rheum Dis 2013; 72: 678-85.
-
(2013)
Ann Rheum Dis
, vol.72
, pp. 678-685
-
-
Ter Haar, N.1
Lachmann, H.2
Ozen, S.3
-
14
-
-
84958822344
-
-
ClinicalTrials.gov: Anakinra for Behçets Disease, [cited 2015 13th July]. Available from
-
ClinicalTrials.gov: Anakinra for Behçets Disease 2011 [cited 2015 13th July]. Available from: https://clinicaltrials.gov/show/NCT01441076.
-
(2011)
-
-
-
15
-
-
0036222477
-
Determination of the minimal clinically important difference in rheumatoid arthritis joint damage of the Sharp/van der Heijde and Larsen/Scott scoring methods by clinical experts and comparison with the smallest detectable difference
-
BRUYNESTEYN K, van der HEIJDE D, BOERS M et al.: Determination of the minimal clinically important difference in rheumatoid arthritis joint damage of the Sharp/van der Heijde and Larsen/Scott scoring methods by clinical experts and comparison with the smallest detectable difference. Arthritis Rheum 2002; 46: 913-20.
-
(2002)
Arthritis Rheum
, vol.46
, pp. 913-920
-
-
Bruynesteyn, K.1
Van Der Heijde, D.2
Boers, M.3
|